Search clinical trials for: Placebo, MK-0431/ONO-5435

Total 1283 results

Ono Pharmaceutical Co. Ltd
MSD K.K.

Completed

MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes

Type 2 Diabetes

Japan
Merck Sharp & Dohme LLC

Recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
Merck Sharp & Dohme LLC

Recruiting

MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Korea, Republic of, Australia, Germany, Spain, Italy, Switzerland, France, Argentina, Colombia, Israel, Austria, Mexico, United Kingdom, Belgium, Turkey, Peru, South Africa
Merck Sharp & Dohme LLC

Completed

MK-5475 in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

Pulmonary Hypertension

United States, Israel, Moldova, Republic of
Merck Sharp & Dohme LLC

Withdrawn

MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

Pneumonia | Coronavirus Disease 2019 (COVID-19) | Hypoxemia
Merck Sharp & Dohme LLC

Completed

A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)

Pulmonary Arterial Hypertension

Moldova, Republic of
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

Type 2 Diabetes Mellitus
Ono Pharmaceutical Co. Ltd

Completed

MK-0431/ONO-5435 Phase III Clinical Trial - Insulin Add-on Study for Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
Eli Lilly and Company

Completed

A Study of LY3819253 (LY-CoV555) in Healthy Participants

Healthy

United States
Merck Sharp & Dohme LLC

Completed

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) (GIANT)

Schizophrenia
Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718) (OD-H)

Alcoholism
Novo Nordisk A/S

Completed

A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels

Healthy Volunteers | Hypercholesterolaemia

United Kingdom
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men

Healthy Volunteers | Atherosclerotic Cardiovascular Disease

Japan
Abide Therapeutics
CogState Ltd.; FGK Clinical Research GmbH; BASi (Bioanalytical Systems, Inc.)

Completed

Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder

Tourette Syndrome | Motor Tic Disorder

Germany, Poland, Spain
Abide Therapeutics
University of Oxford

Completed

An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates

Pain

United Kingdom
Abide Therapeutics

Terminated

A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia

Dyspepsia

Belgium
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects

Healthy

Australia
Abide Therapeutics

Completed

Central Pain Study for ABX-1431

Multiple Sclerosis | Neuromyelitis Optica Spectrum Disorder | Transverse Myelitis | Longitudinally Extensive Transverse Myelitis

United Kingdom
Abide Therapeutics

Completed

A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome

Tourette Syndrome | Chronic Motor Tic Disorder

Germany
Concert Pharmaceuticals

Completed

A Study to Evaluate the Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
RECORDATI GROUP

Completed

Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Neurogenic Detrusor Overactivity

Czechia, France, Poland, Portugal
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)

Alopecia Areata

Spain, United States, Poland, Canada, France, Germany, Hungary
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (THRIVE-AA1)

Alopecia Areata

United States, Canada, Poland, France, Spain
Valo Health, Inc.

Recruiting

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy (Spectra)

Proliferative Diabetic Retinopathy | Non-proliferative Diabetic Retinopathy

United States
Abide Therapeutics

Completed

Titration Study of ABX-1431

Diabetic Peripheral Neuropathy | Small Fiber Neuropathy | Post Herpetic Neuralgia | Post-Traumatic Neuralgia

Moldova, Republic of
Zelos Therapeutics

Withdrawn

A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT)

Hip Fracture

United States
Basking Biosciences, Inc.

Completed

Study of DTRI-031 in Healthy Volunteers

Healthy Volunteers | Pharmacokinetics | Pharmacodynamics

Australia
Merck Sharp & Dohme LLC

Completed

Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) (POMOSCH)

Hepatitis C, Chronic
Basking Biosciences, Inc.

Not yet recruiting

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) (RAISE)

Acute Ischemic Stroke
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

Muscular Atrophy

Canada
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Acceleron Pharma Inc. (a wholly owned subsidiary...

Terminated

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Canada
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Ulcerative Colitis

United States, Georgia, Germany, Hungary, Moldova, Republic of, Poland, Ukraine, United Kingdom

3

Subscribe